xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT06009653</url>
    </required_header>
    <id_info>
      <org_study_id>202209182</org_study_id>
      <nct_id>NCT06009653</nct_id>
    </id_info>
    <brief_title>Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity</brief_title>
    <acronym>TRZ</acronym>
    <official_title>Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Washington University School of Medicine</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
      <collaborator>
        <agency>Eli Lilly and Company</agency>
        <agency_class>Industry</agency_class>
      </collaborator>
    </sponsors>
    <source>Washington University School of Medicine</source>
    <oversight_info>
      <has_dmc>Yes</has_dmc>
      <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
      <is_fda_regulated_device>No</is_fda_regulated_device>
    </oversight_info>
    <brief_summary>
      <textblock>
        The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with&#xD;
        double blind treatment to evaluate the effects of a drug called tirzepatide in combination&#xD;
        with an innovative, culturally-appropriate, intensive lifestyle intervention (ILI) delivered&#xD;
        by community health workers (CHWs) in Latino adults with obesity. Participants will be&#xD;
        randomized to 1) standard care (SC, n=25); 2) culturally-tailored dietary and behavioral&#xD;
        intensive lifestyle intervention (ILI, n=25) provided by CHWs plus placebo; or 3) ILI plus&#xD;
        tirzepatide (ILI-TRZ) for 52 weeks to evaluate the intervention's effect on: i) weight loss;&#xD;
        ii) clinical efficacy (change in body fat mass, liver fat, intra-abdominal fat mass and&#xD;
        intrahepatic triglyceride content, oral glucose tolerance, glycemic control, insulin&#xD;
        sensitivity and b-cell function, plasma lipids, blood pressure, sleep duration, quality and&#xD;
        behaviors, physical performance scores); iii) adherence and fidelity to the intervention&#xD;
        (adherence to the intervention and barriers to long term adherence, quality-of-life, fidelity&#xD;
        of the implementation by CHWs, CHW's and study participants' acceptability and satisfaction&#xD;
        with the intervention and eating behaviors. Placebo or tirzepatide will be injected&#xD;
        subcutaneously in the abdomen or thigh once a week for 12 months.&#xD;
      </textblock>
    </brief_summary>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">August 2023</start_date>
    <completion_date type="Anticipated">November 2025</completion_date>
    <primary_completion_date type="Anticipated">August 2025</primary_completion_date>
    <phase>Phase 4</phase>
    <study_type>Interventional</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <allocation>Randomized</allocation>
      <intervention_model>Parallel Assignment</intervention_model>
      <primary_purpose>Treatment</primary_purpose>
      <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    </study_design_info>
    <primary_outcome>
      <measure>Change in body weight</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Percent change in body weight</description>
    </primary_outcome>
    <primary_outcome>
      <measure>Change in body weight</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Percent change in body weight</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>Proportion of participants losing at least 5% in body weight</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Proportion of participants in each group that lose at least 5% in body weight</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of participants losing at least 5% in body weight</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Proportion of participants in each group that lose at least 5% in body weight</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of participants losing at least 10% in body weight</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Proportion of participants in each group that lose at least 10% in body weight</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of participants losing at least 10% in body weight</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Proportion of participants in each group that lose at least 10% in body weight</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of participants losing at least 15% in body weight</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Proportion of participants in each group that lose at least 15% in body weight</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Proportion of participants losing at least 15% in body weight</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Proportion of participants in each group that lose at least 15% in body weight</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Fat mass and fat free mass</measure>
      <time_frame>Before and after 24 weeks of intervention</time_frame>
      <description>Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Fat mass and fat free mass</measure>
      <time_frame>Before and after 52 weeks of intervention</time_frame>
      <description>Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>β-cell function</measure>
      <time_frame>Before and after 24 weeks of intervention</time_frame>
      <description>β-cell function will be assessed from a modified 3-hour oral glucose tolerance test</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>β-cell function</measure>
      <time_frame>Before and after 52 weeks of intervention</time_frame>
      <description>β-cell function will be assessed from a modified 3-hour oral glucose tolerance test</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Insulin clearance</measure>
      <time_frame>Before and after 24 weeks of intervention</time_frame>
      <description>Insulin clearance will be assessed from a modified 3-hour oral glucose tolerance test</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Insulin clearance</measure>
      <time_frame>Before and after 52 weeks of intervention</time_frame>
      <description>Insulin clearance will be assessed from a modified 3-hour oral glucose tolerance test</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Plasma lipids</measure>
      <time_frame>Before and after 24 weeks of intervention</time_frame>
      <description>Fasting plasma lipid profile will be assessed by routine blood tests</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Plasma lipids</measure>
      <time_frame>Before and after 52 weeks of intervention</time_frame>
      <description>Fasting plasma lipid profile will be assessed by routine blood tests</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood pressure</measure>
      <time_frame>Before and after 24 weeks of intervention</time_frame>
      <description>Systolic and diastolic blood pressure will be measured</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Blood pressure</measure>
      <time_frame>Before and after 52 weeks of intervention</time_frame>
      <description>Systolic and diastolic blood pressure will be measured</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Lifestyle program adherence</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Number of sessions attended</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Lifestyle program adherence</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Number of sessions attended</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Drug/placebo adherence</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Number of injections received</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Drug/placebo adherence</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Number of injections received</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Program acceptability from community health workers and study participants</measure>
      <time_frame>After 24 weeks of intervention</time_frame>
      <description>Community health workers' and study participants' perceptions of program acceptability via questionnaire</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Program acceptability from community health workers and study participants</measure>
      <time_frame>After 52 weeks of intervention</time_frame>
      <description>Community health workers' and study participants' perceptions of program acceptability via questionnaire</description>
    </secondary_outcome>
    <number_of_arms>3</number_of_arms>
    <enrollment type="Anticipated">75</enrollment>
    <condition>Obesity</condition>
    <condition>Metabolic Disease</condition>
    <arm_group>
      <arm_group_label>Standard Care</arm_group_label>
      <arm_group_type>Active Comparator</arm_group_type>
      <description>In this arm, participants will receive the standard care intervention from community health workers.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Intensive lifestyle intervention plus placebo</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>In this arm, participants will receive a culturally-tailored dietary and behavioral intensive lifestyle intervention from community health workers, and will receive placebo subcutaneous injections weekly during the 52-week intervention.</description>
    </arm_group>
    <arm_group>
      <arm_group_label>Intensive lifestyle intervention plus tirzepatide</arm_group_label>
      <arm_group_type>Experimental</arm_group_type>
      <description>In this arm, participants will receive the behavioral plant-based intervention from community health workers, and will receive subcutaneous injections of tirzepatide weekly during the 52-week intervention</description>
    </arm_group>
    <intervention>
      <intervention_type>Behavioral</intervention_type>
      <intervention_name>Standard Care</intervention_name>
      <description>Participants will meet with community health workers to receive general health information through individual check-ins.</description>
      <arm_group_label>Standard Care</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Behavioral</intervention_type>
      <intervention_name>Culturally-tailored dietary and behavioral intensive lifestyle intervention</intervention_name>
      <description>Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.</description>
      <arm_group_label>Intensive lifestyle intervention plus placebo</arm_group_label>
      <arm_group_label>Intensive lifestyle intervention plus tirzepatide</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Placebo</intervention_name>
      <description>Participants will receive placebo subcutaneous injections.</description>
      <arm_group_label>Intensive lifestyle intervention plus placebo</arm_group_label>
    </intervention>
    <intervention>
      <intervention_type>Drug</intervention_type>
      <intervention_name>Tirzepatide</intervention_name>
      <description>Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.</description>
      <arm_group_label>Intensive lifestyle intervention plus tirzepatide</arm_group_label>
    </intervention>
    <eligibility>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            -  Self-reported Hispanic and/or Latino heritage&#xD;
  &#xD;
            -  Body Mass Index (BMI) 30-42 kg/m²&#xD;
  &#xD;
            -  HbA1c ≤ 6.4%&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            -  Previous diagnosis of diabetes or fasting glucose ≥ 126 mg/dl or 2 hr oral glucose&#xD;
               tolerance test plasma glucose ≥ 200 mg/dl&#xD;
  &#xD;
            -  Unstable weight (≥4% during the last 2 months prior to study enrollment)&#xD;
  &#xD;
            -  CPAP treatment for obstructive sleep apnea&#xD;
  &#xD;
            -  Severe cardiovascular disease within the 6 months prior to study enrollment&#xD;
  &#xD;
            -  Severe organ system dysfunction&#xD;
  &#xD;
            -  Known clinically significant gastric emptying abnormality&#xD;
  &#xD;
            -  History of chronic or acute pancreatitis&#xD;
  &#xD;
            -  Thyroid-stimulating hormone (TSH) &gt;1.5X the upper limit of normal&#xD;
  &#xD;
            -  Medical conditions that cause obesity&#xD;
  &#xD;
            -  History of significantly active or unstable Major Depressive Disorder or other severe&#xD;
               psychiatric disorder within the last 2 months&#xD;
  &#xD;
            -  Active substance abuse with alcohol or drugs&#xD;
  &#xD;
            -  Uncontrolled hypertension&#xD;
  &#xD;
            -  Liver disease&#xD;
  &#xD;
            -  Calcitonin level of ≥20 ng/L if eGFR ≥60 mL/min/1.73 m2 or ≥35 ng/L if eGFR &lt;60&#xD;
               mL/min/1.73 m2&#xD;
  &#xD;
            -  Family or personal history of medullary thyroid carcinoma or multiple endocrine&#xD;
               neoplasia syndrome type 2&#xD;
  &#xD;
            -  History of active or untreated malignancy or are in remission from a clinically&#xD;
               significant malignancy (other than basal- or squamous cell skin cancer, in situ&#xD;
               carcinomas of the cervix, or in situ prostate cancer) for less than 5 years&#xD;
  &#xD;
            -  Severe anemia&#xD;
  &#xD;
            -  Pregnant or breastfeeding&#xD;
  &#xD;
            -  Metal implants that preclude MRI testing&#xD;
  &#xD;
            -  Use of medications that are known to affect the study outcome measures&#xD;
  &#xD;
            -  Do not agree to use contraception throughout the study period in male and female&#xD;
               participants of reproductive and childbearing age&#xD;
  &#xD;
            -  Persons who are not able to grant voluntary informed consent&#xD;
  &#xD;
            -  Unable or unwilling to follow the study protocol&#xD;
  &#xD;
            -  Have any other condition not listed in this section (e.g. hypersensitivity or&#xD;
               intolerance) that is a contraindication of GLP-1R agonists&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>21 Years</minimum_age>
      <maximum_age>65 Years</maximum_age>
      <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Miriam Jacome Sosa</last_name>
      <role>Principal Investigator</role>
      <affiliation>Washington University School of Medicine</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Miriam Jacome Sosa, PhD</last_name>
      <phone>(314) 362-4884</phone>
      <email>mjacome@wustl.edu</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Rick Stein, PhD</last_name>
      <phone>314-286-0077</phone>
      <email>rstein@wustl.edu</email>
    </overall_contact_backup>
    <location>
      <facility>
        <name>Sansum Diabetes Research Institute</name>
        <address>
          <city>Santa Barbara</city>
          <state>California</state>
          <zip>93105</zip>
          <country>United States</country>
        </address>
      </facility>
      <contact>
        <last_name>Christian Farfan</last_name>
        <phone>805-335-0411</phone>
        <email>cfarfan@sansum.org</email>
      </contact>
      <contact_backup>
        <last_name>Rebecca Hudson</last_name>
        <phone>805-682-7640</phone>
        <phone_ext>221</phone_ext>
        <email>rhudson@sansum.org</email>
      </contact_backup>
      <investigator>
        <last_name>Kristin Castorino, DO</last_name>
        <role>Principal Investigator</role>
      </investigator>
    </location>
    <location_countries>
      <country>United States</country>
    </location_countries>
    <verification_date>August 2023</verification_date>
    <study_first_submitted>August 19, 2023</study_first_submitted>
    <study_first_submitted_qc>August 19, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 24, 2023</study_first_posted>
    <last_update_submitted>August 19, 2023</last_update_submitted>
    <last_update_submitted_qc>August 19, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 24, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Sponsor</responsible_party_type>
    </responsible_party>
    <keyword>Latinos</keyword>
    <keyword>Obesity</keyword>
    <keyword>Plant-forward diet</keyword>
    <keyword>Tirzepatide</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Obesity</mesh_term>
      <mesh_term>Metabolic Diseases</mesh_term>
      <mesh_term>Body Weight</mesh_term>
    </condition_browse>
    <intervention_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Tirzepatide</mesh_term>
    </intervention_browse>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT06009653
  org study id: 202209182
  nct id: NCT06009653
  lead sponsor: 
  collaborator: 
  has dmc: Yes
  is fda regulated drug: Yes
  is fda regulated device: No
  The purpose of this study is to conduct a three-arm 52-week, randomized controlled trial with
        double blind treatment to evaluate the effects of a drug called tirzepatide in combination
        with an innovative, culturally-appropriate, intensive lifestyle intervention (ILI) delivered
        by community health workers (CHWs) in Latino adults with obesity. Participants will be
        randomized to 1) standard care (SC, n=25); 2) culturally-tailored dietary and behavioral
        intensive lifestyle intervention (ILI, n=25) provided by CHWs plus placebo; or 3) ILI plus
        tirzepatide (ILI-TRZ) for 52 weeks to evaluate the intervention's effect on: i) weight loss;
        ii) clinical efficacy (change in body fat mass, liver fat, intra-abdominal fat mass and
        intrahepatic triglyceride content, oral glucose tolerance, glycemic control, insulin
        sensitivity and b-cell function, plasma lipids, blood pressure, sleep duration, quality and
        behaviors, physical performance scores); iii) adherence and fidelity to the intervention
        (adherence to the intervention and barriers to long term adherence, quality-of-life, fidelity
        of the implementation by CHWs, CHW's and study participants' acceptability and satisfaction
        with the intervention and eating behaviors. Placebo or tirzepatide will be injected
        subcutaneously in the abdomen or thigh once a week for 12 months.
  allocation: Randomized
  intervention model: Parallel Assignment
  primary purpose: Treatment
  masking: Triple (Participant, Investigator, Outcomes Assessor)
  measure: Change in body weight
  time frame: After 24 weeks of intervention
  description: Percent change in body weight
  measure: Change in body weight
  time frame: After 52 weeks of intervention
  description: Percent change in body weight
  measure: Proportion of participants losing at least 5% in body weight
  time frame: After 24 weeks of intervention
  description: Proportion of participants in each group that lose at least 5% in body weight
  measure: Proportion of participants losing at least 5% in body weight
  time frame: After 52 weeks of intervention
  description: Proportion of participants in each group that lose at least 5% in body weight
  measure: Proportion of participants losing at least 10% in body weight
  time frame: After 24 weeks of intervention
  description: Proportion of participants in each group that lose at least 10% in body weight
  measure: Proportion of participants losing at least 10% in body weight
  time frame: After 52 weeks of intervention
  description: Proportion of participants in each group that lose at least 10% in body weight
  measure: Proportion of participants losing at least 15% in body weight
  time frame: After 24 weeks of intervention
  description: Proportion of participants in each group that lose at least 15% in body weight
  measure: Proportion of participants losing at least 15% in body weight
  time frame: After 52 weeks of intervention
  description: Proportion of participants in each group that lose at least 15% in body weight
  measure: Fat mass and fat free mass
  time frame: Before and after 24 weeks of intervention
  description: Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)
  measure: Fat mass and fat free mass
  time frame: Before and after 52 weeks of intervention
  description: Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA)
  measure: β-cell function
  time frame: Before and after 24 weeks of intervention
  description: β-cell function will be assessed from a modified 3-hour oral glucose tolerance test
  measure: β-cell function
  time frame: Before and after 52 weeks of intervention
  description: β-cell function will be assessed from a modified 3-hour oral glucose tolerance test
  measure: Insulin clearance
  time frame: Before and after 24 weeks of intervention
  description: Insulin clearance will be assessed from a modified 3-hour oral glucose tolerance test
  measure: Insulin clearance
  time frame: Before and after 52 weeks of intervention
  description: Insulin clearance will be assessed from a modified 3-hour oral glucose tolerance test
  measure: Plasma lipids
  time frame: Before and after 24 weeks of intervention
  description: Fasting plasma lipid profile will be assessed by routine blood tests
  measure: Plasma lipids
  time frame: Before and after 52 weeks of intervention
  description: Fasting plasma lipid profile will be assessed by routine blood tests
  measure: Blood pressure
  time frame: Before and after 24 weeks of intervention
  description: Systolic and diastolic blood pressure will be measured
  measure: Blood pressure
  time frame: Before and after 52 weeks of intervention
  description: Systolic and diastolic blood pressure will be measured
  measure: Lifestyle program adherence
  time frame: After 24 weeks of intervention
  description: Number of sessions attended
  measure: Lifestyle program adherence
  time frame: After 52 weeks of intervention
  description: Number of sessions attended
  measure: Drug/placebo adherence
  time frame: After 24 weeks of intervention
  description: Number of injections received
  measure: Drug/placebo adherence
  time frame: After 52 weeks of intervention
  description: Number of injections received
  measure: Program acceptability from community health workers and study participants
  time frame: After 24 weeks of intervention
  description: Community health workers' and study participants' perceptions of program acceptability via questionnaire
  measure: Program acceptability from community health workers and study participants
  time frame: After 52 weeks of intervention
  description: Community health workers' and study participants' perceptions of program acceptability via questionnaire
  arm group label: Standard Care
  arm group type: Active Comparator
  description: In this arm, participants will receive the standard care intervention from community health workers.
  arm group label: Intensive lifestyle intervention plus placebo
  arm group type: Experimental
  description: In this arm, participants will receive a culturally-tailored dietary and behavioral intensive lifestyle intervention from community health workers, and will receive placebo subcutaneous injections weekly during the 52-week intervention.
  arm group label: Intensive lifestyle intervention plus tirzepatide
  arm group type: Experimental
  description: In this arm, participants will receive the behavioral plant-based intervention from community health workers, and will receive subcutaneous injections of tirzepatide weekly during the 52-week intervention
  intervention type: Behavioral
  intervention name: Standard Care
  description: Participants will meet with community health workers to receive general health information through individual check-ins.
  arm group label: Standard Care
  intervention type: Behavioral
  intervention name: Culturally-tailored dietary and behavioral intensive lifestyle intervention
  description: Participants will meet with community health workers to receive information focused on healthy eating while still adhering to a culturally-tailored plant-forward diet.
  arm group label: Intensive lifestyle intervention plus placebo
  arm group label: Intensive lifestyle intervention plus tirzepatide
  intervention type: Drug
  intervention name: Placebo
  description: Participants will receive placebo subcutaneous injections.
  arm group label: Intensive lifestyle intervention plus placebo
  intervention type: Drug
  intervention name: Tirzepatide
  description: Participants will receive subcutaneous injections of tirzepatide that gradually increase up to 15 mg per week.
  arm group label: Intensive lifestyle intervention plus tirzepatide
  criteria: 
  gender: All
  minimum age: 21 Years
  maximum age: 65 Years
  healthy volunteers: Accepts Healthy Volunteers
  last name: Miriam Jacome Sosa
  role: Principal Investigator
  affiliation: Washington University School of Medicine
  last name: Miriam Jacome Sosa, PhD
  phone: (314) 362-4884
  email: mjacome@wustl.edu
  last name: Rick Stein, PhD
  phone: 314-286-0077
  email: rstein@wustl.edu
  facility: 
  contact: 
  contact backup: 
  investigator: 
  country: United States
  responsible party type: Sponsor
  mesh term: Obesity
  mesh term: Metabolic Diseases
  mesh term: Body Weight
  mesh term: Tirzepatide